IMNM Insider Trading
Insider Ownership Percentage: 8.60%
Insider Buying (Last 12 Months): $2,265,265.18
Insider Selling (Last 12 Months): $279,313.12
Immunome Share Price & Price History
Current Price: $8.93
Price Change: ▼ Price Decrease of -0.28 (-3.04%)
As of 03/13/2025 05:00 PM ET
Immunome Insider Trading History
Immunome Institutional Trading History
Data available starting January 2016
Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Read More on Immunome
Volume
494,077 shs
Average Volume
905,366 shs
Market Capitalization
$712.41 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.93
Who are the company insiders with the largest holdings of Immunome?
Who are the major institutional investors of Immunome?
Immunome's top institutional investors include:
- T. Rowe Price Investment Management Inc. — 6.89%
- Redmile Group LLC — 6.05%
- Enavate Sciences GP LLC — 4.36%
- Janus Henderson Group PLC — 4.33%
- Vanguard Group Inc. — 3.76%
- Price T Rowe Associates Inc. MD — 2.86%
Learn More about top institutional investors of Immunome stock.
Which institutional investors are selling Immunome stock?
During the previous quarter, IMNM stock was sold by these institutional investors:
- Invesco Ltd.
- T. Rowe Price Investment Management Inc.
- Marshall Wace LLP
- Vanguard Group Inc.
- Redmile Group LLC
- Bank of America Corp DE
- Jane Street Group LLC
- Janus Henderson Group PLC
During the previous year, company insiders that have sold Immunome company stock include:
- Clay B Siegall (CEO)
- Max Rosett (CFO)
Learn More investors selling Immunome stock.
Which institutional investors are buying Immunome stock?
Within the previous quarter, IMNM stock was bought by institutional investors including:
- Enavate Sciences GP LLC
- JPMorgan Chase & Co.
- Granahan Investment Management LLC
- Renaissance Technologies LLC
- Adage Capital Partners GP L.L.C.
- Price T Rowe Associates Inc. MD
- Point72 Asset Management L.P.
- Millennium Management LLC
During the previous year, these company insiders have bought Immunome stock:
- Clay B Siegall (CEO)
- Max Rosett (CFO)
- Bruce Turner (Insider)
- Philip Tsai (CTO)
- Jean Jacques Bienaime (Director)
Learn More investors buying Immunome stock.